Navigation Links
VA and Louisiana State University Announce Site Selections for New Orleans Medical Center Projects
Date:11/25/2008

WASHINGTON, Nov. 25 /PRNewswire-USNewswire/ -- In a public event held today in New Orleans, the Department of Veterans Affairs (VA) and the State of Louisiana jointly announced the selection of adjacent downtown sites for construction of their replacement medical center projects. The two projects, called the Veterans Affairs Medical Center and the Louisiana State University Academic Medical Center, restore greatly needed health care capability lost in New Orleans during flooding after Hurricane Katrina in late August 2005.

"Restoring a full capability medical center for our veterans in New Orleans and southeastern Louisiana is one of the Secretary's highest priorities," said Deputy Secretary of Veterans Affairs Gordon H. Mansfield. "Site selection is a key milestone in the project delivery process."

"VA selected the downtown site because it offers the best solution for our veterans, today and into the future," Mansfield added. "The site, located within a robust medical district with affiliate health care teaching universities, promotes long term operational synergy and efficiency. The selected site aligns with the City of New Orleans and State of Louisiana Hurricane Katrina recovery and redevelopment plans."

An agreement between VA and the City of New Orleans obligates the city to acquire the land for the new facility, prepare the site for construction and turn over the site to VA within one year.

"I understand this site selection creates near term impact on the directly affected and surrounding neighborhoods," Mansfield continued. "We have been working cooperatively with federal, state, city and neighborhood partners to develop a robust package of treatment measures to mitigate the negative impacts and invest in new local opportunities."

"Constructing this state-of-the-art medical complex near downtown New Orleans follows through on the Administra
'/>"/>

SOURCE U.S. Department of Veterans Affairs
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. WellPoint Adjusts Health and Pharmacy Guidelines for Members in Texas and Louisiana Affected by Hurricane Ike
2. ACS Facilitates Emergency Prescription Assistance Program Now Activated in Southern Louisiana
3. CVS/pharmacy Re-Opens 64 Stores in Louisiana
4. NOAA and Louisiana scientists predict largest Gulf of Mexico dead zone on record
5. Louisiana Department of Health and Hospitals Announces Intent to Award Cost Containment Services Contract to HMS
6. Louisiana Improves Law for Treating Mentally Ill
7. CRH Medical Corporation opens center in New Orleans, Louisiana
8. Louisiana May Mandate Fluoridation Despite Evidence of Harm
9. Asbestos Verdict Upheld by Louisiana Court of Appeal, Announces Baron & Budd
10. Hospitals in Louisiana and Mississippi to Receive More Katrina Recovery Grants
11. Louisiana Advisor to Speak Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Growth hormone is used to treat twice as many short boys than girls in the US and Asia 2Health News:Growth hormone is used to treat twice as many short boys than girls in the US and Asia 3Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 3Health News:U-M study: Work hassles hamper sleep 2Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 2Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 3Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 4Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 5Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 6Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 7Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 8Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 9Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 10Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 11Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 12Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 13Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 14Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 15Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 16Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 17Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 18Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 19Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 20Health News:Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data 2Health News:Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data 3
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3AMD LASERS Announces Partnerships With Three Industry Leading Companies 5686 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 2Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 3Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 1Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 2
Other Medicine Technology:New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7